Phenotyping of congenic dipeptidyl peptidase 4 (DP4) deficient Dark Agouti (DA) rats suggests involvement of DP4 in neuro-, endocrine, and immune functions

Clinical Chemistry and Laboratory Medicine

Volumn 47, Issue 3, 2009, Pages 275-287

  Frerker, Nadine ^a   Raber, Kerstin ^a,b   Bode, Felix ^a   Skripuletz, Thomas ^a   Nave, Heike ^a   Klemann, Christian ^a   Pabst, Reinhard ^a   Stephan, Michael ^a,c   Schade, Jutta ^a   Brabant, Georg ^a   Wedekind, Dirk ^a   Jacobs, Roland ^a   Jörns, Anne ^a   Forssmann, Ulf ^a   Straub, Rainer H ^d   Johannes, Sigrid ^e   Hoffmann, Torsten ^f   Wagner, Leona ^f   Demuth, Hans Ulrich ^f   Von Hörsten, Stephan ^a,b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Clinic for Psychosomatic and Psychotherapy   (Germany)

^d UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^e MERCK KGAA   (Germany)

^f PROBIODRUG AG   (Germany)

Author keywords

Comprehensive phenotyping; Dipeptidyl peptidase 4; Inhibitors; Neuropeptide Y

Indexed keywords

AMINOTRANSFERASE; CORTICOTROPIN; CYTOKINE; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; INTERLEUKIN 10; INTERLEUKIN 6; LEPTIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DARK AGOUTI RAT; ENDOCRINE FUNCTION; ENZYME ACTIVITY; FEMALE; GLUCOSE TOLERANCE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LEUKOCYTE; LYMPHOCYTE FUNCTION; MALE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; T LYMPHOCYTE; WEIGHT GAIN;

ANIMALS; ANIMALS, CONGENIC; ANTIGENS, CD26; BODY WEIGHT; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; GLUCAGON-LIKE PEPTIDE 1; KILLER CELLS, NATURAL; LEPTIN; PHENOTYPE; RATS; RATS, INBRED F344; T-LYMPHOCYTES; TRANSAMINASES; TRIGLYCERIDES;

AGOUTI; ANIMALIA; RATTUS;

EID: 63849165577     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2009.064     Document Type: Article

References (51)

1. Weber AE. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J Med Chem 2004;47:4135-41.
2. Karl T, Hoffmann T, Pabst R, von Horsten S. Extreme reduction of dipeptidyl peptidase IV activity in F344 rat substrains is associated with various behavioral differences. Physiol Behav 2003;80:123-34.
3. Karl T, Pabst R, von Horsten S. Behavioral phenotyping of mice in pharmacological and toxicological research. Exp Toxicol Pathol 2003;55:69-83.
4. Karl T, Chwalisz WT, Wedekind D, Hedrich HJ, Hoffmann T, Jacobs R, et al. Localization, transmission, spontaneous mutations, and variation of function of the Dpp4 (Dipeptidyl-peptidase IV; CD26) gene in rats. Regul Pept 2003;115:81-90.
5. Karl T, Hoffmann T, Pabst R, von Horsten S. Behavioral effects of neuropeptide Y in F344 rat substrains with a reduced dipeptidyl-peptidase IV activity. Pharmacol Biochem Behav 2003;75:869-79.
6. Kruschinski C, Skripuletz T, Bedoui S, Tschernig T, Pabst R, Nassenstein C, et al. CD26 (dipeptidyl-peptidase IV)- dependent recruitment of T cells in a rat asthma model. Clin Exp Immunol 2005;139:17-24.
7. Shingu K, Helfritz A, Zielinska-Skowronek M, Meyer- Olson D, Jacobs R, Schmidt RE, et al. CD26 expression determines lung metastasis in mutant F344 rats: involvement of NK cell function and soluble CD26. Cancer Immunol Immunother 2003;52:546-54.
8. Tsuji E, Misumi Y, Fujiwara T, Takami N, Ogata S, Ikehara Y. An active-site mutation (Gly633→Arg) of dipeptidyl peptidase IV causes its retention and rapid degradation in the endoplasmic reticulum. Biochemistry 1992;31:11921-7.
9. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 2000;97:6874-9.
10. Abbott A. Laboratory animals: the Renaissance rat. Nature 2004;428:464-6.
11. Jacob HJ, Kwitek AE. Rat genetics: attaching physiology and pharmacology to the genome. Nat Rev Genet 2002; 3:33-42.
12. Nguyen HP, Kobbe P, Rahne H, Worpel T, Jager B, Stephan M, et al. Behavioral abnormalities precede neuropathological markers in rats transgenic for Huntington's disease. Hum Mol Genet 2006;15:3177-94.
13. von Horsten S, Schmitt I, Nguyen HP, Holzmann C, Schmidt T, Walther T, et al. Transgenic rat model of Huntington's disease. Hum Mol Genet 2003;12:617-24.
14. Mentlein R. Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept 1999;85: 9-24.
15. De Meester I, Korom S, Van Damme J, Scharpe S. CD26, let it cut or cut it down. Immunol Today 1999;20:367-75.
16. Moser B, Wolf M, Walz A, Loetscher P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol 2004;25:75-84.
17. Nathan DM. Finding new treatments for diabetes - how many, how fast how good? N Engl J Med 2007;356: 437-40.
18. Tiruppathi C, Miyamoto Y, Ganapathy V, Leibach FH. Genetic evidence for role of DPP IV in intestinal hydrolysis and assimilation of prolyl peptides. Am J Physiol 1993;265:G81-9.
19. Frerker N, Wagner L, Wolf R, Heiser U, Hoffmann T, Rahfeld JU, et al. Neuropeptide Y (NPY) cleaving enzymes: structural and functional homologues of dipeptidyl peptidase 4. Peptides 2007;28:257-68.
20. Lewandowski K, Horn R, O'Callaghan CJ, Dunlop D, Medley GF, O'Hare P, et al. Free leptin, bound leptin, and soluble leptin receptor in normal and diabetic pregnancies. J Clin Endocrinol Metab 1999;84:300-6.
21. Goldmann T, Burgemeister R, Sauer U, Loeschke S, Lang DS, Branscheid D, et al. Enhanced molecular analyses by combination of the HOPE-technique and laser microdissection. Diagn Pathol 2006;1:2.
22. Brabant G, Nave H, Horn R, Anderwald C, Muller G, Roden M. In vivo and in vitro evidence for a hepatic modulation of the leptin signal in rats. Eur J Clin Invest 2004;34:831-7.
23. Breivik T, Stephan M, Brabant GE, Straub RH, Pabst R, von Horsten S. Postnatal lipopolysaccharide-induced illness predisposes to periodontal disease in adulthood. Brain Behav Immun 2002;16:421-38.
24. Kask A, Nguyen HP, Pabst R, von Horsten S. Factors influencing behavior of group-housed male rats in the social interaction test: focus on cohort removal. Physiol Behav 2001;74:277-82.
25. Straub RH, Schaller T, Miller LE, von Horsten S, Jessop DS, Falk W, et al. Neuropeptide Y cotransmission with norepinephrine in the sympathetic nerve-macrophage interplay. J Neurochem 2000;75:2464-71.
26. Shingu K, Helfritz A, Kuhlmann S, Zielinska-Skowronek M, Jacobs R, Schmidt RE, et al. Kinetics of the early recruitment of leukocyte subsets at the sites of tumor cells in the lungs: natural killer (NK) cells rapidly attract monocytes but not lymphocytes in the surveillance of micrometastasis. Int J Cancer 2002;99:74-81.
27. von Horsten S, Ballof J, Helfritz F, Nave H, Meyer D, Schmidt RE, et al. Modulation of innate immune functions by intracerebroventricularly applied neuropeptide Y: dose and time dependent effects. Life Sci 1998;63: 909-22.
28. Bryant J, Day R, Whiteside TL, Herberman RB. Calculation of lytic units for the expression of cell-mediated cytotoxicity. J Immunol Methods 1992;146:91-103.
29. Lankas GR, Leiting B, Roy RS, Eiermann GJ, Beconi MG, Biftu T, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005;54:2988-94.
30. Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, Lynn FC, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 2003;52: 741-50.
31. Ahren B, Holst JJ, Martensson H, Balkan B. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol 2000; 404:239-45.
32. Conarello SL, Li Z, Ronan J, Roy RS, Zhu L, Jiang G, et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci USA 2003;100:6825-30.
33. Brabant G, Muller G, Horn R, Anderwald C, Roden M, Nave H. Hepatic leptin signaling in obesity. FASEB J 2005;19:1048-50.
34. Ruter J, Hoffmann T, Demuth HU, Moschansky P, Klapp BF, Hildebrandt M. Evidence for an interaction between leptin, T cell costimulatory antigens CD28, CTLA-4 and CD26 (dipeptidyl peptidase IV) in BCG-induced immune responses of leptin- and leptin receptor-deficient mice. Biol Chem 2004;385:537-41.
35. Girardi AC, Knauf F, Demuth HU, Aronson PS. Role of dipeptidyl peptidase IV in regulating activity of Naq/Hq exchanger isoform NHE3 in proximal tubule cells. Am J Physiol Cell Physiol 2004;287:C1238-45.
36. Tiruppathi C, Miyamoto Y, Ganapathy V, Roesel RA, Whitford GM, Leibach FH. Hydrolysis and transport of proline-containing peptides in renal brush-border membrane vesicles from dipeptidyl peptidase IV-positive and dipeptidyl peptidase IV-negative rat strains. J Biol Chem 1990;265:1476-83.
37. Erickson RH, Suzuki Y, Sedlmayer A, Kim YS. Biosynthesis and degradation of altered immature forms of intestinal dipeptidyl peptidase IV in a rat strain lacking the enzyme. J Biol Chem 1992;267:21623-9.
38. Broxmeyer HE, Hangoc G, Cooper S, Campbell T, Ito S, Mantel C. AMD3100 and CD26 modulate mobilization, engraftment, and survival of hematopoietic stem and progenitor cells mediated by the SDF-1/CXCL12-CXCR4 axis. Ann NY Acad Sci 2007;1006:1-19.
39. Bedoui S, Kuhlmann S, Nave H, Drube J, Pabst R, von Horsten S. Differential effects of neuropeptide Y (NPY) on leukocyte subsets in the blood: mobilization of B-1-like B-lymphocytes and activated monocytes. J Neuroimmunol 2001;117:125-32.
40. Yan S, Marguet D, Dobers J, Reutter W, Fan H. Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen. Eur J Immunol 2003;33:1519-27.
41. Ohnuma K, Uchiyama M, Yamochi T, Nishibashi K, Hosono O, Takahashi N, et al. Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1. J Biol Chem 2007;282:10117-31.
42. Preller V, Gerber A, Wrenger S, Togni M, Marguet D, Tadje J, et al. TGF-beta1-mediated control of central nervous system inflammation and autoimmunity through the inhibitory receptor CD26. J Immunol 2007; 178:4632-40.
43. Reinhold D, Bank U, Buhling F, Lendeckel U, Faust J, Neubert K, et al. Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth factor-beta 1 in PWM-stimulated PBMC and T cells. Immunology 1997; 91:354-60.
44. Mu J, Woods J, Zhou YP, Roy RS, Li Z, Zycband E, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic {beta}-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006;55:1695-704.
45. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995; 269:543-6.
46. Rosenbaum M, Goldsmith R, Bloomfield D, Magnano A, Weimer L, Heymsfield S, et al. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest 2005;115:3579-86.
47. Jarmolowska B, Bielikowicz K, Iwan M, Sidor K, Kostyra E, Kaczmarski M. Serum activity of dipeptidyl peptidase IV (DPPIV; EC 3.4.14.5) in breast-fed infants with symptoms of allergy. Peptides 2007;28:678-82.
48. Kask A, Harro J, von Horsten S, Redrobe JP, Dumont Y, Quirion R. The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y. Neurosci Biobehav Rev 2002;26:259-83.
49. horsell A, Michalkiewicz M, Dumont Y, Quirion R, Caberlotto L, Rimondini R, et al. Behavioral insensitivity to restraint stress, absent fear suppression of behavior and impaired spatial learning in transgenic rats with hippocampal neuropeptide Y overexpression. Proc Natl Acad Sci USA 2000;97:12852-7.
50. Christopherson KW II, Hangoc G, Mantel CR, Broxmeyer HE. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 2004;305:1000-3.
51. Dimitrijevic M, Stanojevic S, Vujic V, Kovacevic-Jovanovic V, Beck-Sickinger A, Demuth H, et al. Effect of neuropeptide Y on inflammatory paw edema in the rat: involvement of peripheral NPY Y1 and Y5 receptors and interaction with dipeptidyl-peptidase IV (CD26). J Neuroimmunol 2002;129:35-42.